TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01042379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucatinib plus trastuzumab and pertuzumab
Description: Arm is closed. Tucatinib: 300 mg PO BID 12 weeks CLOSED Tucatinib: 250 mg PO BID 12 weeks CLOSED Tucatinib adaptive: 150mg BID days 1-28, 250mg BID days 29-84 Trastuzumab: 4 mg/kg IV (loading dose) cycle 1; 2 mg/kg (thereafter) cycles 2-12 Pertuzumab: 840 mg IV (loading dose) cycle 1; 420 mg (thereafter) cycles 4, 7 and 10 Paclitaxel: 80 mg/m2 IV cycles 1-12 Doxorubicin + Cyclophosphamide: Cycles 13-16; Doxorubicin: 60 mg/m2 IV Every 2 or 3 weeks for 4 cycles; Cyclophosphamide: 600 mg/m2 IV Every 2 or 3 weeks for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Cemiplimab: 350 mg q3w X 12 weeks IV cycles 1,4,7,10 Paclitaxel: 80 mg/m2 IV cycles 1-12 Doxorubicin + Cyclophosphamide: Cycles 13-16; Doxorubicin: 60 mg/m2 IV Every 2 or 3 weeks for 4 cycles; Cyclophosphamide: 600 mg/m2 IV Every 2 or 3 weeks for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab plus REGN3767
Description: Cemiplimab: 350 mg q3w X 12 weeks IV cycles 1,4,7,10 REGN 3767: 1600 mg q3W X 12 weeks IV cycles 1,4,7,10 Paclitaxel: 80 mg/m2 IV cycles 1-12 Doxorubicin + Cyclophosphamide: Cycles 13-16; Doxorubicin: 60 mg/m2 IV Every 2 or 3 weeks for 4 cycles; Cyclophosphamide: 600 mg/m2 IV Every 2 or 3 weeks for 4 cycles
Study: NCT01797536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir
Study: NCT03447171

Intervention type: DEVICE
Intervention: App Vision Screening
Description: Using GoCheck Kids App Vision Screening to detect Amblyopia Risk Factors
Study: NCT00797992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection
Description: Intravitreal injection of 1.25 mg bevacizumab
Study: NCT00668681

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EndoRefix
Study: NCT02994342

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal gel, Medical Device Class 2A
Description: Application twice a day of vaginal gel for 56 consecutive days
Study: NCT01558882

Intervention type: DEVICE
Intervention: Essure
Description: Essure devices are deployed according to manufacturer's instructions for tubal sterilization.
Study: NCT02514252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Sublingual Spray (FSS)
Description: Stage 1: First Pain Episode - Single dose of breakthrough opioid given from existing PCA pump equivalent to 10% of their MEDD.~Second Pain Episode - Single dose of FSS equivalent to 16-32% of MEDD. If not effective at 30 minutes, participant repeats same dose one more time (with a cap of 1600 mcg total; i.e. dose given 30 minutes ago + dose now = 1600 mcg maximum.~Third Pain Episode (at least 4 hours after second episode) - Participant required 2 breakthrough FSS doses for the last episode of breakthrough pain, or if the effective dose has not been identified, he/she will double the last administered dose. If breakthrough pain not effective at 30 minutes, participant repeats same dose one more time (with a cap of 1600 mcg total; i.e. dose given 30 minutes ago + dose now = 1600 mcg maximum).~Stage 2: If FSS successful in hospital, upon discharge, FSS used as first choice of pain medication instead of oral pain medication for pain for up to 4 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Symptom questionnaire completed at baseline and after last dose of FSS while hospitalized. After Day 28, questionnaire completed over the phone about participant's opinion of research study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mental Ability Tests
Description: Mental ability tests given while hospitalized 30 minutes after first dose of current pain medication, and 30 minutes after each FSS dose.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Study Diary
Description: Participants given study diary to document pain level, how many times FSS used, and any side effects experienced each day.
Study: NCT04447092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m2 iv D1, 8, 15 (every 4 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel 125 mg/m2 iv D1, 8, 15 (every 4 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab ( 200 ) mg iv D1 (every 3 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab ( 200 ) mg iv D1 (every 3 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 65 mg/m2 iv over 2 hours D1 (every 2 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Leucovorin 400 mg/m2 iv D1 (every 2 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 140 mg/m2 iv over 1.5 hours D1 (every 2 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5FU
Description: 5-FU 2400 mg/m2 iv over 46 hours D1 (every 2 weeks)
Study: NCT02720913

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: COR-KNOT
Description: The COR-KNOT device was developed to make suture fixation faster and save operative time. With a single squeeze of the lever, the device remotely and automatically secures sutures with a titanium fastener, while also simultaneously trimming excess suture tails.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Suture Tying
Description: Standard Suture Tying
Study: NCT02148003

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RFA at 90 degrees Celsius
Description: Ablation at 90 degrees Celsius is defined as radiofrequency ablation of the lumbar facets nerve supply will be performed at 90 degrees Celsius

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RFA at 80 degrees Celsius
Description: Ablation at 80 degrees Celsius is defined as radiofrequency ablation of the lumbar facets nerve supply will be performed at 80 degrees Celsius

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: C-arm guided 20-gauge radiofrequency needle
Description: Needles will be adjusted to optimize sensory and motor stimulation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: C-arm guided 20-gauge radiofrequency needle
Description: Needles will be adjusted to optimize sensory and motor stimulation.
Study: NCT04453124

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Topical antiseptic treatment
Description: Prevent the development of bacterial cutaneous ulcers by applying antiseptic sap from Ficus septica tree on small wounds.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Topical antiseptic treatment
Description: Prevent the development of bacterial cutaneous ulcers by applying antiseptic sap from Ficus septica tree on small wounds.
Study: NCT03641573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C] ASN002
Description: \[14C\] ASN002
Study: NCT00749424

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SES
Description: CYPHER SELECT™ Sirolimus-eluting Balloon-expandable Coronary Stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SES
Description: CYPHER SELECT™ Sirolimus-eluting Balloon-expandable Coronary Stent
Study: NCT01894828

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional supplements
Description: Patients are asked to drink two 200ml bottles of nutritional supplement daily for 14 days before surgery
Study: NCT02840877

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: DOT Adherence Monitoring
Description: Study participants will meet with a study-employed DOT worker daily during weekdays throughout the course of their TB treatment
Study: NCT00349596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Administered intravenously (IV) over 1 hour at 10 mg/m2 daily x 5 days every other week.
Study: NCT01697436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin [Copegus]
Description: tablet under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin [Copegus]
Description: tablet under fasted condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin [Copegus]
Description: oral solution under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin [Copegus]
Description: oral solution under fasted condition
Study: NCT03683134

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Description: Participants will receive nutrition education and educational materials from a registered dietitian on patients on the patterns of a Mediterranean style diet. Seven education sessions will be delivered through an online platform. Participants will be asked to complete one education session per week for the first six weeks and the final session at week 9.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Olive oil and mixed nuts
Description: Participants in the Mediterranean diet group will receive 3 liters of extra-virgin olive oil and 3 pounds of mixed nuts (1.5 pounds raw almonds and 1.5 pounds raw walnuts) at baseline and at 6 weeks. Participants will be educated by oral and written means, on consumption goals of the nuts and olive oil.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: American Heart Association
Description: Participants will receive nutrition education and educational materials from a registered dietitian on patients on the dietary recommendations from the American Heart Association for heart health. Seven education sessions will be delivered through an online platform. Participants will be asked to complete one education session per week for the first six weeks and the final session at week 9.
Study: NCT04510116

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adults in the Making program
Description: The AIM prevention program, modeled after an existing family-based skills-training intervention in a group format for rural African American preadolescents, consists of six consecutive weekly group meetings held at community facilities, with separate parent and youth skill-building curricula and a family curriculum. Each of the six meetings includes separate, concurrent training sessions for parents and youth, followed by a joint parent-youth session during which the families practice the skills they learned in their separate sessions. Concurrent and family sessions each last 1 hour. Thus, both parents and youth receive 12 hours of prevention training.
Study: NCT00087568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 1000/1200mg po bid for 36 or 60 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 1000/1200mg po bid for 36 or 60 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 micrograms weekly for 36 weeks (non-responders) or 60 weeks (non-tolerators)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 micrograms weekly for 36 weeks (non-responders) or 60 weeks (non-tolerators)
Study: NCT03948685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol SR
Description: blood pressure, heart rate based titrated carvedilol SR for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00058240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvocidib
Description: Given IV
Study: NCT03018353

Intervention type: DRUG
Group type: OTHER
Intervention: Patients receiving Sof/Vel (Epclusa) and Navigation services
Description: Implementing HCV treatment in the jails using FDA-approved medications and continuing there treatment in the community if they are released during their treatment regimen.
Study: NCT03754257

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental Electrical Stimulation
Description: Experimental Electrical Stimulation (100Hz) during 40 minutes

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Electrical Stimulation
Description: Sham Electrical Stimulation (5Hz) during 40 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Physiotherapy
Description: Active and passive exercises, and walking.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Conventional Physiotherapy
Description: Active and passive exercises, and walking.
Study: NCT04085822

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SMA-001
Description: Intra-dermal injection of SMA-001 and control device.
Study: NCT01470469

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPD503 (extended-release Guanfacine hydrochloride)
Description: Once-daily oral dosing of SPD503 in the evening ranging from 1-6 mg for 12 weeks (6 week dose optimization and 6 week dose maintenance).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once-daily oral dosing in the evening for 12 weeks.
Study: NCT00111228

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Guardian RT

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Guardian RT

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SMBG only
Description: SMBG only
Study: NCT00475007

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IBV® Valve System
Description: The IBV Valve is a small, umbrella shaped device designed to redirect airflow to healthier areas of the lungs. It is implanted without incisions using a bronchoscope.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: IBV® Valve System
Description: The IBV Valve is a small, umbrella shaped device designed to redirect airflow to healthier areas of the lungs. It is implanted without incisions using a bronchoscope.
Study: NCT01670162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: Intravitreal Injection 2mg/0.05mL Aflibercept
Study: NCT03192150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISV-305
Description: Dexamethasone in DuraSite® 2 twice daily for 16 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle twice daily for 16 days
Study: NCT02232659

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 70cc TAH-t for Destination Therapy
Description: Use of the approved SynCardia 70cc TAH-t for patients who are in biventricular failure (approved use), but who are ineligible for cardiac transplant (experimental use).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 70cc TAH-t for Destination Therapy
Description: Use of the approved SynCardia 70cc TAH-t for patients who are in biventricular failure (approved use), but who are ineligible for cardiac transplant (experimental use).
Study: NCT02579616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib will be administered orally once daily in 28-day cycles. Participants will be treated until disease progression, unacceptable toxicity, withdrawal of consent, participant's choice, etc.
Study: NCT05082194

Intervention type: PROCEDURE
Intervention: balance with open and closed eyes
Description: The UNTERBERGER TEST. The subjects performed the test once with their eyes open and then with their eyes closed. The participant's task was to assume a standing position with legs apart at hip-width and then walk in place (50 steps).~Static and dynamic balance testing on the Biodex SD balance platform. Moreover, both during the Unterberger functional test and the tests on the Biodex SD balance platform, the muscle tone was assessed in the subjects using the Luna EMG device. Before starting the tests, surface electrodes were glued to the patient's body (according to the SENIAM procedure). Five surface electrodes were used, consisting of three channels. They were placed on the abdomen of the right sternocleidomastoid muscle, two more were placed on the left longus colli muscle, and one reference electrode on the right shoulder process of the scapula. After each completed test, an ongoing test report was generated.

Intervention type: PROCEDURE
Intervention: balance with open and closed eyes
Description: The UNTERBERGER TEST. The subjects performed the test once with their eyes open and then with their eyes closed. The participant's task was to assume a standing position with legs apart at hip-width and then walk in place (50 steps).~Static and dynamic balance testing on the Biodex SD balance platform. Moreover, both during the Unterberger functional test and the tests on the Biodex SD balance platform, the muscle tone was assessed in the subjects using the Luna EMG device. Before starting the tests, surface electrodes were glued to the patient's body (according to the SENIAM procedure). Five surface electrodes were used, consisting of three channels. They were placed on the abdomen of the right sternocleidomastoid muscle, two more were placed on the left longus colli muscle, and one reference electrode on the right shoulder process of the scapula. After each completed test, an ongoing test report was generated.
Study: NCT02100007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ME-344
Description: Part 1: ME-344 IV at 10 mg/kg on Days 1, 8, 15, and 22 of each 28-day cycle. Part 2: ME-344 IV at the dose defined in Part 1 on Days 1, 8, 15, and 22 of each 28 day cycle.~Patients will be allowed to continue receiving ME-344 infusions weekly according to the assigned dose level as long as there is clinical benefit to the patient as assessed by the Investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Part 1: Topotecan 4 mg/m2 i.v. weekly on Days 1, 8 and 15 of each 28-day cycle. Part 2: Topotecan 4 mg/m2 i.v. weekly on Days 1, 8 and 15 of each 28-day cycle.
Study: NCT01117727

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brain Computer Interface Switch
Description: Subjects will wear an EEG cap for 1-2 hours typical per session and use the brain computer interface to operate assistive technology. Subjects will be asked to participate in 14-20 sessions.
Study: NCT02537964

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: washcloths impregnated with 2% chlorhexidine gluconate
Description: All infants in the NICU eligible for the study will be assigned for bathing three times a week with washcloths impregnated with 2% chlorhexidine gluconate
Study: NCT01147419

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stent
Description: Before operation, take aspirin 100mg every day. During the operation, stent is delivered by a catheter and positioned through the narrowing in the artery. The stent is then expanded against the wall of the blood vessel to provide a wider channel for blood. At last, use balloon dilate the stent.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: femoral-popliteal bypass with artificial blood vessel
Description: Before operation, take aspirin 100mg every day. Groin and suprageniculate incision, PTFE graft with end to side anastomoses.
Study: NCT01885481

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: epidural steroid injection using dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betamethasone
Description: epidural steroid injection using betamethasone
Study: NCT01448850

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI8968 600 mg IV, 300 mg SC
Description: MEDI8968 600 mg as IV infusion on Day 1 followed by 300 mg injection SC every 4 weeks up to Week 53.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to MEDI8968 as IV infusion on Day 1 followed by SC injection every 4 weeks up to Week 53.
Study: NCT02714452

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Person-centred care
Description: Person-centred and thriving promoting care
Study: NCT02596529

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fixation
Description: Fixation of the posterior malleolus with lag-screws or platefixation (usually by Drittelrohr plate).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NO Fixation
Description: NO Fixation of the posterior malleolus.
Study: NCT01042379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trilaciclib with or without trastuzumab + pertuzumab
Description: Trilaciclib: 240 mg/m2 IV weekly cycle 1-16 Paclitaxel: 80 mg/m2 IV cycles 1-12 Doxorubicin + Cyclophosphamide: Cycles 13-16; Doxorubicin: 60 mg/m2 IV Every 2 or 3 weeks for 4 cycles; Cyclophosphamide: 600 mg/m2 IV Every 2 or 3 weeks for 4 cycles~For HER2+:~Pertuzumab: 840 mg IV (loading dose) week 1 and 420 mg every 3 weeks (weeks 4, 7, 10) post-randomization Trastuzumab: 4 mg/kg (loading dose) week 1 and 2 mg/kg weekly (weeks 2-12) post-randomization

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYD985 ([vic-]trastuzumab duocarmazine)
Description: SYD985: 1.2 mg/kg IV (q3w x 12 weeks) cycles 1,4,7,10 Doxorubicin + Cyclophosphamide: Cycles 13-16; Doxorubicin: 60 mg/m2 IV Every 2 or 3 weeks for 4 cycles; Cyclophosphamide: 600 mg/m2 IV Every 2 or 3 weeks for 4 cycles
Study: NCT04400513

Intervention type: DEVICE
Intervention: Use of Eko CORE and Eko DUO electronic stethoscopes
Description: Auscultation of heart sounds using electronic stethoscopes

Intervention type: DEVICE
Intervention: Use of Eko CORE and Eko DUO electronic stethoscopes
Description: Auscultation of heart sounds using electronic stethoscopes

Intervention type: DEVICE
Intervention: Use of Eko CORE and Eko DUO electronic stethoscopes
Description: Auscultation of heart sounds using electronic stethoscopes

Intervention type: DEVICE
Intervention: Use of Eko CORE and Eko DUO electronic stethoscopes
Description: Auscultation of heart sounds using electronic stethoscopes

Intervention type: DEVICE
Intervention: Use of Eko CORE and Eko DUO electronic stethoscopes
Description: Auscultation of heart sounds using electronic stethoscopes

Intervention type: DEVICE
Intervention: Use of Eko CORE and Eko DUO electronic stethoscopes
Description: Auscultation of heart sounds using electronic stethoscopes
Study: NCT04917302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NMDAE plus AIFA
Description: Use of an NMDA enhancer plus a drug with anti-inflammatory property for the treatment of schizophrenia.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NMDAE plus Placebo Cap
Description: Use of an NMDA enhancer plus placebo as a comparator